Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AbbVie/J&J’s Imbruvica Marches Toward Front-Line CLL Indication With sNDA

This article was originally published in The Pink Sheet Daily

Executive Summary

AbbVie submitted a filing for Imbruvica in front-line CLL based on the results of the Phase III RESONATE trial showing the BTK inhibitor demonstrated progression-free survival in newly diagnosed patients.

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register